Clinical Overview > Condition/ Syndrome > Bilateral adrenal hyperplasia

You are looking at 1 - 5 of 5 items

Lima Lawrence Departments of Endocrinology, Diabetes & Metabolism, Cleveland Clinic, Cleveland, Ohio, USA

Search for other papers by Lima Lawrence in
Google Scholar
PubMed
Close
,
Peng Zhang Departments of Pulmonary Medicine & Critical Care, Cleveland Clinic, Cleveland, Ohio, USA

Search for other papers by Peng Zhang in
Google Scholar
PubMed
Close
,
Humberto Choi Departments of Pulmonary Medicine & Critical Care, Cleveland Clinic, Cleveland, Ohio, USA

Search for other papers by Humberto Choi in
Google Scholar
PubMed
Close
,
Usman Ahmad Departments of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio, USA

Search for other papers by Usman Ahmad in
Google Scholar
PubMed
Close
,
Valeria Arrossi Departments of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio, USA

Search for other papers by Valeria Arrossi in
Google Scholar
PubMed
Close
,
Andrei Purysko Departments of Diagnostic Radiology, Cleveland Clinic, Cleveland, Ohio, USA

Search for other papers by Andrei Purysko in
Google Scholar
PubMed
Close
, and
Vinni Makin Departments of Endocrinology, Diabetes & Metabolism, Cleveland Clinic, Cleveland, Ohio, USA

Search for other papers by Vinni Makin in
Google Scholar
PubMed
Close

Summary

Ectopic adrenocorticotropic hormone (ACTH) production leading to ectopic ACTH syndrome accounts for a small proportion of all Cushing’s syndrome (CS) cases. Thymic neuroendocrine tumors are rare neoplasms that may secrete ACTH leading to rapid development of hypercortisolism causing electrolyte and metabolic abnormalities, uncontrolled hypertension and an increased risk for opportunistic infections. We present a unique case of a patient who presented with a mediastinal mass, revealed to be an ACTH-secreting thymic neuroendocrine tumor (NET) causing ectopic CS. As the diagnosis of CS from ectopic ACTH syndrome (EAS) remains challenging, we emphasize the necessity for high clinical suspicion in the appropriate setting, concordance between biochemical, imaging and pathology findings, along with continued vigilant monitoring for recurrence after definitive treatment.

Learning points:

  • Functional thymic neuroendocrine tumors are exceedingly rare.

  • Ectopic Cushing’s syndrome secondary to thymic neuroendocrine tumors secreting ACTH present with features of hypercortisolism including electrolyte and metabolic abnormalities, uncontrolled hypertension and hyperglycemia, and opportunistic infections.

  • The ability to undergo surgery and completeness of resection are the strongest prognostic factors for improved overall survival; however, the recurrence rate remains high.

  • A high degree of initial clinical suspicion followed by vigilant monitoring is required for patients with this challenging disease.

Open access
Su Ann Tee Department of Endocrinology, Newcastle Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK

Search for other papers by Su Ann Tee in
Google Scholar
PubMed
Close
,
Earn Hui Gan Department of Endocrinology, Newcastle Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, UK

Search for other papers by Earn Hui Gan in
Google Scholar
PubMed
Close
,
Mohamad Zaher Kanaan Departments of Ophthalmology, Newcastle Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK

Search for other papers by Mohamad Zaher Kanaan in
Google Scholar
PubMed
Close
,
David Ashley Price Departments of Infectious Disease and Tropical Medicine, Newcastle Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK

Search for other papers by David Ashley Price in
Google Scholar
PubMed
Close
,
Tim Hoare Radiology, Newcastle Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK

Search for other papers by Tim Hoare in
Google Scholar
PubMed
Close
, and
Simon H S Pearce Department of Endocrinology, Newcastle Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, UK

Search for other papers by Simon H S Pearce in
Google Scholar
PubMed
Close

Summary

Primary adrenal insufficiency secondary to syphilis is extremely rare, with only five cases being reported in the literature. We report a case of adrenal insufficiency as a manifestation of Treponema pallidum infection (tertiary syphilis). A 69-year-old, previously fit and well Caucasian male was found to have adrenal insufficiency after being admitted with weight loss, anorexia and postural dizziness resulting in a fall. Biochemical testing showed hyponatraemia, hyperkalaemia, and an inadequate response to Synacthen testing, with a peak cortisol level of 302 nmol/L after administration of 250 µg Synacthen. Abdominal imaging revealed bilateral adrenal hyperplasia with inguinal and retroperitoneal lymphadenopathy. He was started on hydrocortisone replacement; however, it was not until he re-attended ophthalmology with a red eye and visual loss 1 month later, that further work-up revealed the diagnosis of tertiary syphilis. Following a course of penicillin, repeat imaging 5 months later showed resolution of the abnormal radiological appearances. However, adrenal function has not recovered and 3 years following initial presentation, the patient remains on both glucocorticoid and mineralocorticoid replacement. In conclusion, this case highlights the importance of considering syphilis as a potential differential diagnosis in patients presenting with adrenal insufficiency and bilateral adrenal masses, given the recent re-emergence of this condition. The relative ease of treating infectious causes of adrenal lesions makes accurate and timely diagnosis crucial.

Learning points:

  • Infectious causes, including syphilis, should be excluded before considering adrenalectomy or biopsy for any patient presenting with an adrenal mass.

  • It is important to perform a full infection screen including tests for human immunodeficiency virus, other blood-borne viruses and concurrent sexually transmitted diseases in patients presenting with bilateral adrenal hyperplasia with primary adrenal insufficiency.

  • Awareness of syphilis as a potential differential diagnosis is important, as it not only has a wide range of clinical presentations, but its prevalence has been increasing in recent times.

Open access
Charlotte Boughton Endocrinology Department of Clinical Biochemistry (Viapath), King’s College Hospital NHS Foundation Trust, London, UK

Search for other papers by Charlotte Boughton in
Google Scholar
PubMed
Close
,
David Taylor Department of Clinical Biochemistry (Viapath), King’s College Hospital NHS Foundation Trust, London, UK

Search for other papers by David Taylor in
Google Scholar
PubMed
Close
,
Lea Ghataore Department of Clinical Biochemistry (Viapath), King’s College Hospital NHS Foundation Trust, London, UK

Search for other papers by Lea Ghataore in
Google Scholar
PubMed
Close
,
Norman Taylor Department of Clinical Biochemistry (Viapath), King’s College Hospital NHS Foundation Trust, London, UK

Search for other papers by Norman Taylor in
Google Scholar
PubMed
Close
, and
Benjamin C Whitelaw Endocrinology Department of Clinical Biochemistry (Viapath), King’s College Hospital NHS Foundation Trust, London, UK

Search for other papers by Benjamin C Whitelaw in
Google Scholar
PubMed
Close

Summary

We describe severe hypokalaemia and hypertension due to a mineralocorticoid effect in a patient with myelodysplastic syndrome taking posaconazole as antifungal prophylaxis. Two distinct mechanisms due to posaconazole are identified: inhibition of 11β hydroxylase leading to the accumulation of the mineralocorticoid hormone 11-deoxycorticosterone (DOC) and secondly, inhibition of 11β hydroxysteroid dehydrogenase type 2 (11βHSD2), as demonstrated by an elevated serum cortisol-to-cortisone ratio. The effects were ameliorated by spironolactone. We also suggest that posaconazole may cause cortisol insufficiency. Patients taking posaconazole should therefore be monitored for hypokalaemia, hypertension and symptoms of hypocortisolaemia, at the onset of treatment and on a monthly basis. Treatment with mineralocorticoid antagonists (spironolactone or eplerenone), supplementation of glucocorticoids (e.g. hydrocortisone) or dose reduction or cessation of posaconazole should all be considered as management strategies.

Learning points:

  • Combined hypertension and hypokalaemia are suggestive of mineralocorticoid excess; further investigation is appropriate.

  • If serum aldosterone is suppressed, then further investigation to assess for an alternative mineralocorticoid is appropriate, potentially using urine steroid profiling and/or serum steroid panelling.

  • Posaconazole can cause both hypokalaemia and hypertension, and we propose that this is due to two mechanisms – both 11β hydroxylase inhibition and 11β HSD2 inhibition.

  • Posaconazole treatment may lead to cortisol insufficiency, which may require treatment; however, in this clinical case, the effect was mild.

  • First-line treatment of this presentation would likely be use of a mineralocorticoid antagonist.

  • Patients taking posaconazole should be monitored for hypertension and hypokalaemia on initiation and monthly thereafter.

Open access
Teresa Rego Endocrinology Department, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central, Lisbon, Portugal

Search for other papers by Teresa Rego in
Google Scholar
PubMed
Close
,
Fernando Fonseca Endocrinology Department, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central, Lisbon, Portugal

Search for other papers by Fernando Fonseca in
Google Scholar
PubMed
Close
,
Stéphanie Espiard Endocrinology Department, INSERM U1016, Institut Cochin, Paris Descartes University, & Center for Rare Adrenal Diseases, Hôpital Cochin, APHP-Paris, France

Search for other papers by Stéphanie Espiard in
Google Scholar
PubMed
Close
,
Karine Perlemoine Endocrinology Department, INSERM U1016, Institut Cochin, Paris Descartes University, & Center for Rare Adrenal Diseases, Hôpital Cochin, APHP-Paris, France

Search for other papers by Karine Perlemoine in
Google Scholar
PubMed
Close
,
Jérôme Bertherat Endocrinology Department, INSERM U1016, Institut Cochin, Paris Descartes University, & Center for Rare Adrenal Diseases, Hôpital Cochin, APHP-Paris, France

Search for other papers by Jérôme Bertherat in
Google Scholar
PubMed
Close
, and
Ana Agapito Endocrinology Department, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central, Lisbon, Portugal

Search for other papers by Ana Agapito in
Google Scholar
PubMed
Close

Summary

PBMAH is a rare etiology of Cushing syndrome (CS). Familial clustering suggested a genetic cause that was recently confirmed, after identification of inactivating germline mutations in armadillo repeat-containing 5 (ARMC5) gene. A 70-year-old female patient was admitted due to left femoral neck fracture in May 2014, in Orthopedics Department. During hospitalization, hypertension (HTA) and hypokalemia were diagnosed. She presented with clinical signs of hypercortisolism and was transferred to the Endocrinology ward for suspected CS. Laboratory workup revealed: ACTH <5 pg/mL; urinary free cortisol (UFC), 532 µg/24 h (normal range: 20–90); failure to suppress the low-dose dexamethasone test (0.5 mg every 6 h for 48 h): cortisol 21 µg/dL. Abdominal magnetic resonance imaging (MRI) showed enlarged nodular adrenals (right, 55 × 54 × 30 mm; left, 85 × 53 × 35 mm), and she was submitted to bilateral adrenalectomy. In 2006, this patient’s 39-year-old daughter had been treated by one of the authors. She presented with severe clinical and biological hypercortisolism. Computed tomography (CT) scan showed massively enlarged nodular adrenals with maximal axis of 15 cm for both. Bilateral adrenalectomy was performed. In this familial context of PBMAH, genetic study was performed. Leucocyte DNA genotyping identified in both patients the same germline heterozygous ARMC5 mutation in exon 1 c.172_173insA p.I58Nfs*45. The clinical cases herein described have an identical phenotype with severe hypercortisolism and huge adrenal glands, but different ages at the time of diagnosis. Current knowledge of inheritance of this disease, its insidious nature and the well-known deleterious effect of hypercortisolism favor genetic study to timely identify and treat these patients.

Learning points:

  • PBMAH is a rare etiology of CS, characterized by functioning adrenal macronodules and variable cortisol secretion.

  • The asymmetric/asynchronous involvement of only one adrenal gland can also occur, making disease diagnosis a challenge.

  • Familial clustering suggests a genetic cause that was recently confirmed, after identification of inactivating germline mutations in armadillo repeat-containing 5 (ARMC5) gene.

  • The insidious nature of this disease and the well-known deleterious effect of hypercortisolism favor genetic study of other family members, to diagnose and treat these patients timely.

  • As ARMC5 is expressed in many organs and recent findings suggest an association of PBMAH and meningioma, a watchful follow-up is required.

Open access
Maura Bucciarelli Department of Medicine, Lehigh Valley Health Network, Allentown, Pennsylvania, 18103, USA

Search for other papers by Maura Bucciarelli in
Google Scholar
PubMed
Close
,
Ya-Yu Lee Division of Endocrinology, Department of Medicine, Lehigh Valley Health Network, Allentown, Pennsylvania, 18103, USA

Search for other papers by Ya-Yu Lee in
Google Scholar
PubMed
Close
, and
Vasudev Magaji Division of Endocrinology, Department of Medicine, Lehigh Valley Health Network, Allentown, Pennsylvania, 18103, USA

Search for other papers by Vasudev Magaji in
Google Scholar
PubMed
Close

Summary

Ectopic ACTH secretion from breast cancer is extremely rare. We report a case of a 30-year-old woman with a history of breast cancer, who presented with psychosis and paranoid behaviour. CT of the head showed white matter disease consistent with posterior reversible encephalopathy syndrome (PRES). Despite using mifepristone with multiple antihypertensives including lisinopril, spironolactone and metoprolol, she was hypertensive. Transaminitis did not allow mifepristone dose escalation and ketoconazole utilization. Etomidate infusion at a non-sedating dose in the intensive care unit controlled her hypertension and cortisol levels. She was transitioned to metyrapone and spironolactone. She was discharged from the hospital on metyrapone with spironolactone and underwent chemotherapy. She died 9 months later after she rapidly redeveloped Cushing's syndrome and had progressive metastatic breast cancer involving multiple bones, liver and lungs causing respiratory failure.

Learning points

  • Cushing's syndrome from ectopic ACTH secreting breast cancer is extremely rare.

  • Cushing's syndrome causing psychosis could be multifactorial including hypercortisolism and PRES.

  • Etomidate at non-sedating doses in intensive care setting can be effective to reduce cortisol production followed by transition to oral metyrapone.

Open access